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PRO evidence is paramount. Adoption of PRO data by national and international can-
cer guidelines is key for centralized markets. Literature review findings corroborated 
with payer interviews indicated that inclusion of PRO data for crizotinib was crucial 
to achieving a price premium in Germany, with additional benefit based on PRO data 
on symptoms and quality of life. ConClusions: There is growing recognition that 
the patient perspective is important in market access decision making in central-
ized markets and PRO data can be a key differentiator among therapeutic options.
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objeCtives: The European Union Directive (2011/24/EU) requires member states 
to establish pathways that enable patients to receive reimbursed treatment in 
another European Union country. These cross-border access pathways are becom-
ing increasingly relevant for highly specialised medical technologies such as proton 
beam therapy and gene therapy, which are delivered by only a handful of provid-
ers across Europe. The objectives of our study were to understand how approvals 
for reimbursed cross-border treatments in the context of highly specialised treat-
ments work in Germany, and to identify any barriers and practical steps to overcome 
these. Methods: We have investigated the case-by-case access decision pathway for 
German patients to receive highly specialised treatments in another country using 
secondary research, and awareness surveys with Health Care Practitioners. Results: 
We found the biggest barrier for cross-border treatment access are delays in the 
case-by-case approval process caused by (a) low awareness of cross-border access 
pathways amongst Health Care Practitioners, (b) the lack of well-defined guidelines 
on how to make the case for medical need, and (c) case-by-case reimbursement 
negotiations between the sickness fund and the treatment provider in the other 
country. ConClusions: To overcome these barriers we suggest manufacturers 
and/or the provider of the highly specialised treatment to engage with the MDK 
(Medizinischer Dienst der Krankenkassen - Medical Service of Health Insurance) to 
define the requirements of the patient dossier, and to agree a checklist to bring a 
degree of objectivity in to medical need assessment. Additionally, we suggest work-
ing with the major sickness funds to negotiate a reimbursement rate, in advance 
of the first patient being identified for the treatment. Establishing these processes 
and making Health Care Practitioners aware of them would reduce approval times 
for German patients to access highly specialised treatments delivered in another 
EU member state.
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objeCtives: Within the German hospital landscape (in-patient), NUBs (Neue 
Untersuchungs- und Behandlungsmethoden) [new treatment and examination 
methods] represent a key method to achieve reimbursement for new, cost-intensive 
drugs, medical products or procedures. NUBs are paid on top of hospital budget and 
hence represent additional funding for hospitals. The objective of this analysis was 
to provide an overview on the proportion of drugs (vs. methods, medicinal prod-
ucts) and their respective indications for 2015 and compare these to the results 
of 2014. Methods: The German DRG database issued by the InEK (Institute for 
Hospital Remuneration System) is used to analyse NUB subgroups sorted according 
to key therapeutic indications for the years 2015 and 2014. Additionally the number 
of NUB 1 (positive status) products that went through the AMNOG process up to 
June 2015 is being analysed. Results: Out of 670 NUB submissions 159 (24%) are 
classified as drugs in 2015. Results for the year 2014 were 618 NUB submissions with 
133 (22%) drugs. The analysis also compares proportion of drugs in different NUB 
classification levels for 2015 and 2014 (NUB 1-4). Leading therapeutic areas are iden-
tified. Chances to grant a successfull NUB 1 status approval for drugs and procedures 
are examined. Out of 56 drugs that were given NUB 1 status, 29 (52%) had passed 
through AMNOG process until June 2015. 43 drugs with NUB status 1 and 24 (55%) 
that had passed the early benefit assessment by June 2014 (55%). ConClusions: 
Drug applications are more likely than procedures to be given NUB 1 status and 
thereby initiate reimbursement negotiations with the SHI. Results of 2015 confirm 
the findings for 2014. Oncology products showed the highest success rates in two 
consecutive years. Oncology products are often high priced therapies and use the 
NUB system to enter the G-DRG system for future reimbursement.
PHP199
are vaccinationS really DiFFerent to PHarmaceuticalS WitH reSPect 
to market acceSS in germany?
Droeschel D1, Vollmer L1, Krone FA2, Walzer S1
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2State University 
Baden-Wuerttemberg, Loerrach, Germany
objeCtives: Although AMNOG was introduced to reorganize the medicine prod-
ucts market, it is not applicable for vaccines. Immunization in Germany is organized 
de-centrally under the responsibility of the social health insurance. The aim of this 
study was to analyze the market access route and compare that to the AMNOG pro-
cess. Methods: The market access route was analyzed systematically and mapped 
the pathway by identifying key processes, stakeholders, applicable regulations and 
laws, pricing and negotiation setting and supply chain conditions. Results: Based 
on the results of the systematic analysis we could ascertain specifics for the vaccina-
tion market. The Standing Committee on Immunisation (STIKO) by the Robert Koch 
Institute decides regularly on vaccination recommendations. Vaccinations are obliga-
tory provisions of the SHIs and based on a regulation within with the G-BA defines 
details and requirements, type and scope. Further, SHIs can provide optional benefits 
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objeCtives: The economic evaluation of new medicines is substantial for allo-
cating the limited healthcare budgets. In Bulgaria, according to the legislation for 
pricing and reimbursement of medicinal products applied to be included in the 
Positive Drug List, pharmacoeconomic assessment shall be performed according 
to the criteria based on efficacy, therapeutic effectiveness, safety, and pharmaco-
economic parameters. However, until recently there were no detailed guidelines 
for applicants available and in April 2015 methodological recommendations were 
implemented. The objective of methodological recommendations is to achieve 
optimal assessment of candidate medicinal products applying for the PDL inclu-
sion. Methods: A working group of representatives from National Council for 
Pricing and Reimbursement of medicinal products, Bulgarian Drug Agency, and 
experts from academia developed a guideline, following the good practices of other 
countries to provide standardized approach to economic evaluation of medicinal 
products in Bulgaria. Results: The guideline is structured in five sections including 
requirements for provided data for efficacy, therapeutic effectiveness and safety, as 
well as pharmacoeconomic parameters. Applicants need to prepare their applica-
tions according to the requirements provided by these methodological recommen-
dations.There should be a clear and unambiguous conclusion about the benefits 
of the medicinal product, subject to evaluation over the existing alternatives, the 
clinical significance and its place in therapy. If there is an economic evaluations 
conducted with a candidate medicinal product for other health systems or pub-
lished by HTA agencies in Europe it is necessary to be provided with respective 
motives for positive or negative decision. ConClusions: The implemented phar-
macoeconomic guideline will facilitate the appraisal of medicinal products based 
on objective and transparent information which will allow the decision makers to 
justify the reimbursement of new medicinal products based on scientific evidences 
and available resources.
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objeCtives: Before biosimilars entered the market the decision making process 
for payers regarding generics was straightforward. As the active pharmaceutical 
ingredient was the same molecule, a cheaper generic version would always be 
more cost-effective than its original counterpart. This changed with the upcoming 
of biosimilars of erythropoiesis-stimulating agents. Several publications pointed 
to differences in effectiveness between original and generic versions. Therefore, 
a payer no longer could solely rely on price comparison, but had to factor the effi-
cacy difference when he was trying to limit drug expenditures. The question arose 
whether the efficacy gaps are only observed in erythropoetins or are general for all 
biologicals. Methods: We searched the scientific literature and the EMA database 
for comparative studies for all currently approved biosimilars in Europe. Data for the 
quantity needed to reach a given therapeutic effect, was extracted. Subsequently 
the prices from a German payers perspective were taken from official tariffs and 
applied to the price-efficacy-equation. Results: Until Q1/2015 19 biosimilars were 
granted market authorization in Europe. Analysis showed that erythropoetins are 
the only ones with relevant efficacy differences between originator and generic 
version. All other biosimilar agents were equivalent to the reference drug according 
to EMA standards. Price information was not available for three drugs currently not 
marketed in Germany. For all other drugs the prices of the generic versions were 
significantly below the originator version resulting in a better price-efficacy-ratio 
for the biosimilars. ConClusions: Except for erythropoetin biosimilars no differ-
ences in efficacy could be observed in the analyzed study data. Therefore it seems 
legitimate for payers to limit their view to the price in the price-efficacy-ratio when 
making reimbursement decisions regarding biosimilars.
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objeCtives: To understand how PRO data from clinical trials are utilized in market 
access decision making in oncology and other disease areas in markets with central-
ized healthcare systems. Methods: PubMed/MEDLINE, Embase, ISPOR databases, 
and regulatory and HTA websites for the EMA, the UK, France, and Germany were 
searched to identify PRO data included in regulatory and HTA submissions of four 
oncology drugs: bevacizumab, pemetrexed, sunitinib, and crizotinib. One-on-one 
interviews were conducted with 10 payers from different countries with centralized 
healthcare systems in 2014. An online assessment was conducted (December 8, 2014, 
to March 4, 2015) with 5 completed surveys (China, France, Germany, Taiwan, the UK) 
and 2 partially completed surveys (Australia and South Korea) by payers from the 
RTI Health Solutions Global Payer Advisory Panel. Results: Reviews of HTA and 
reimbursement decisions indicate that HTA bodies have varying levels of familiarity 
and confidence in PRO data. All 10 payers indicated that it is worthwhile to collect PRO 
data in clinical trials for oncology, particularly in phase 3 and postmarketing studies. 
Payers speculated that PRO data will increase in importance over the next 5-10 years 
and could be a key differentiator for new therapies. Payers offered little differentiation 
in the importance of PRO data by cancer type. Payers indicated that the quality of the 
